Biopharmaceutical Cmo-EMEA Market Status and Trend Report 2013-2023
Report Summary
Biopharmaceutical Cmo-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biopharmaceutical Cmo industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Biopharmaceutical Cmo 2013-2017, and development forecast 2018-2023
Main market players of Biopharmaceutical Cmo in EMEA, with company and product introduction, position in the Biopharmaceutical Cmo market
Market status and development trend of Biopharmaceutical Cmo by types and applications
Cost and profit status of Biopharmaceutical Cmo, and marketing status
Market growth drivers and challenges
The report segments the EMEA Biopharmaceutical Cmo market as:
EMEA Biopharmaceutical Cmo Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Biopharmaceutical Cmo Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Biologics
Biosimilars
EMEA Biopharmaceutical Cmo Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Contract Manufacturing
Contract Research
EMEA Biopharmaceutical Cmo Market: Players Segment Analysis (Company and Product introduction, Biopharmaceutical Cmo Sales Volume, Revenue, Price and Gross Margin):
Lonza
Boehringer Ingelheim GmbH
Rentschler Biotechnologie GmbH
Inno Biologics Sdn Bhd
JRS Pharma (Celonic GmbH)
BIOMEVA GmbH
ProBioGen
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
TOYOBO CO., LTD
Samsung BioLogics
Patheon
CMC Biologics
Binex Co., Ltd.
AbbVie Inc.
WuXi Biologics.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Biopharmaceutical Cmo-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biopharmaceutical Cmo industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Biopharmaceutical Cmo 2013-2017, and development forecast 2018-2023
Main market players of Biopharmaceutical Cmo in EMEA, with company and product introduction, position in the Biopharmaceutical Cmo market
Market status and development trend of Biopharmaceutical Cmo by types and applications
Cost and profit status of Biopharmaceutical Cmo, and marketing status
Market growth drivers and challenges
The report segments the EMEA Biopharmaceutical Cmo market as:
EMEA Biopharmaceutical Cmo Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Biopharmaceutical Cmo Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Biologics
Biosimilars
EMEA Biopharmaceutical Cmo Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Contract Manufacturing
Contract Research
EMEA Biopharmaceutical Cmo Market: Players Segment Analysis (Company and Product introduction, Biopharmaceutical Cmo Sales Volume, Revenue, Price and Gross Margin):
Lonza
Boehringer Ingelheim GmbH
Rentschler Biotechnologie GmbH
Inno Biologics Sdn Bhd
JRS Pharma (Celonic GmbH)
BIOMEVA GmbH
ProBioGen
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
TOYOBO CO., LTD
Samsung BioLogics
Patheon
CMC Biologics
Binex Co., Ltd.
AbbVie Inc.
WuXi Biologics.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BIOPHARMACEUTICAL CMO
1.1 Definition of Biopharmaceutical Cmo in This Report
1.2 Commercial Types of Biopharmaceutical Cmo
1.2.1 Biologics
1.2.2 Biosimilars
1.3 Downstream Application of Biopharmaceutical Cmo
1.3.1 Contract Manufacturing
1.3.2 Contract Research
1.4 Development History of Biopharmaceutical Cmo
1.5 Market Status and Trend of Biopharmaceutical Cmo 2013-2023
1.5.1 EMEA Biopharmaceutical Cmo Market Status and Trend 2013-2023
1.5.2 Regional Biopharmaceutical Cmo Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Biopharmaceutical Cmo in EMEA 2013-2017
2.2 Consumption Market of Biopharmaceutical Cmo in EMEA by Regions
2.2.1 Consumption Volume of Biopharmaceutical Cmo in EMEA by Regions
2.2.2 Revenue of Biopharmaceutical Cmo in EMEA by Regions
2.3 Market Analysis of Biopharmaceutical Cmo in EMEA by Regions
2.3.1 Market Analysis of Biopharmaceutical Cmo in Europe 2013-2017
2.3.2 Market Analysis of Biopharmaceutical Cmo in Middle East 2013-2017
2.3.3 Market Analysis of Biopharmaceutical Cmo in Africa 2013-2017
2.4 Market Development Forecast of Biopharmaceutical Cmo in EMEA 2018-2023
2.4.1 Market Development Forecast of Biopharmaceutical Cmo in EMEA 2018-2023
2.4.2 Market Development Forecast of Biopharmaceutical Cmo by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Biopharmaceutical Cmo in EMEA by Types
3.1.2 Revenue of Biopharmaceutical Cmo in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Biopharmaceutical Cmo in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Biopharmaceutical Cmo in EMEA by Downstream Industry
4.2 Demand Volume of Biopharmaceutical Cmo by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biopharmaceutical Cmo by Downstream Industry in Europe
4.2.2 Demand Volume of Biopharmaceutical Cmo by Downstream Industry in Middle East
4.2.3 Demand Volume of Biopharmaceutical Cmo by Downstream Industry in Africa
4.3 Market Forecast of Biopharmaceutical Cmo in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOPHARMACEUTICAL CMO
5.1 EMEA Economy Situation and Trend Overview
5.2 Biopharmaceutical Cmo Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOPHARMACEUTICAL CMO MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Biopharmaceutical Cmo in EMEA by Major Players
6.2 Revenue of Biopharmaceutical Cmo in EMEA by Major Players
6.3 Basic Information of Biopharmaceutical Cmo by Major Players
6.3.1 Headquarters Location and Established Time of Biopharmaceutical Cmo Major Players
6.3.2 Employees and Revenue Level of Biopharmaceutical Cmo Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOPHARMACEUTICAL CMO MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Lonza
7.1.1 Company profile
7.1.2 Representative Biopharmaceutical Cmo Product
7.1.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Lonza
7.2 Boehringer Ingelheim GmbH
7.2.1 Company profile
7.2.2 Representative Biopharmaceutical Cmo Product
7.2.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
7.3 Rentschler Biotechnologie GmbH
7.3.1 Company profile
7.3.2 Representative Biopharmaceutical Cmo Product
7.3.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Rentschler Biotechnologie GmbH
7.4 Inno Biologics Sdn Bhd
7.4.1 Company profile
7.4.2 Representative Biopharmaceutical Cmo Product
7.4.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Inno Biologics Sdn Bhd
7.5 JRS Pharma (Celonic GmbH)
7.5.1 Company profile
7.5.2 Representative Biopharmaceutical Cmo Product
7.5.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of JRS Pharma (Celonic GmbH)
7.6 BIOMEVA GmbH
7.6.1 Company profile
7.6.2 Representative Biopharmaceutical Cmo Product
7.6.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of BIOMEVA GmbH
7.7 ProBioGen
7.7.1 Company profile
7.7.2 Representative Biopharmaceutical Cmo Product
7.7.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of ProBioGen
7.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
7.8.1 Company profile
7.8.2 Representative Biopharmaceutical Cmo Product
7.8.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
7.9 TOYOBO CO., LTD
7.9.1 Company profile
7.9.2 Representative Biopharmaceutical Cmo Product
7.9.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of TOYOBO CO., LTD
7.10 Samsung BioLogics
7.10.1 Company profile
7.10.2 Representative Biopharmaceutical Cmo Product
7.10.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Samsung BioLogics
7.11 Patheon
7.11.1 Company profile
7.11.2 Representative Biopharmaceutical Cmo Product
7.11.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Patheon
7.12 CMC Biologics
7.12.1 Company profile
7.12.2 Representative Biopharmaceutical Cmo Product
7.12.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of CMC Biologics
7.13 Binex Co., Ltd.
7.13.1 Company profile
7.13.2 Representative Biopharmaceutical Cmo Product
7.13.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Binex Co., Ltd.
7.14 AbbVie Inc.
7.14.1 Company profile
7.14.2 Representative Biopharmaceutical Cmo Product
7.14.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of AbbVie Inc.
7.15 WuXi Biologics.
7.15.1 Company profile
7.15.2 Representative Biopharmaceutical Cmo Product
7.15.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of WuXi Biologics.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOPHARMACEUTICAL CMO
8.1 Industry Chain of Biopharmaceutical Cmo
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOPHARMACEUTICAL CMO
9.1 Cost Structure Analysis of Biopharmaceutical Cmo
9.2 Raw Materials Cost Analysis of Biopharmaceutical Cmo
9.3 Labor Cost Analysis of Biopharmaceutical Cmo
9.4 Manufacturing Expenses Analysis of Biopharmaceutical Cmo
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOPHARMACEUTICAL CMO
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Biopharmaceutical Cmo in This Report
1.2 Commercial Types of Biopharmaceutical Cmo
1.2.1 Biologics
1.2.2 Biosimilars
1.3 Downstream Application of Biopharmaceutical Cmo
1.3.1 Contract Manufacturing
1.3.2 Contract Research
1.4 Development History of Biopharmaceutical Cmo
1.5 Market Status and Trend of Biopharmaceutical Cmo 2013-2023
1.5.1 EMEA Biopharmaceutical Cmo Market Status and Trend 2013-2023
1.5.2 Regional Biopharmaceutical Cmo Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Biopharmaceutical Cmo in EMEA 2013-2017
2.2 Consumption Market of Biopharmaceutical Cmo in EMEA by Regions
2.2.1 Consumption Volume of Biopharmaceutical Cmo in EMEA by Regions
2.2.2 Revenue of Biopharmaceutical Cmo in EMEA by Regions
2.3 Market Analysis of Biopharmaceutical Cmo in EMEA by Regions
2.3.1 Market Analysis of Biopharmaceutical Cmo in Europe 2013-2017
2.3.2 Market Analysis of Biopharmaceutical Cmo in Middle East 2013-2017
2.3.3 Market Analysis of Biopharmaceutical Cmo in Africa 2013-2017
2.4 Market Development Forecast of Biopharmaceutical Cmo in EMEA 2018-2023
2.4.1 Market Development Forecast of Biopharmaceutical Cmo in EMEA 2018-2023
2.4.2 Market Development Forecast of Biopharmaceutical Cmo by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Biopharmaceutical Cmo in EMEA by Types
3.1.2 Revenue of Biopharmaceutical Cmo in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Biopharmaceutical Cmo in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Biopharmaceutical Cmo in EMEA by Downstream Industry
4.2 Demand Volume of Biopharmaceutical Cmo by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biopharmaceutical Cmo by Downstream Industry in Europe
4.2.2 Demand Volume of Biopharmaceutical Cmo by Downstream Industry in Middle East
4.2.3 Demand Volume of Biopharmaceutical Cmo by Downstream Industry in Africa
4.3 Market Forecast of Biopharmaceutical Cmo in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOPHARMACEUTICAL CMO
5.1 EMEA Economy Situation and Trend Overview
5.2 Biopharmaceutical Cmo Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOPHARMACEUTICAL CMO MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Biopharmaceutical Cmo in EMEA by Major Players
6.2 Revenue of Biopharmaceutical Cmo in EMEA by Major Players
6.3 Basic Information of Biopharmaceutical Cmo by Major Players
6.3.1 Headquarters Location and Established Time of Biopharmaceutical Cmo Major Players
6.3.2 Employees and Revenue Level of Biopharmaceutical Cmo Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOPHARMACEUTICAL CMO MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Lonza
7.1.1 Company profile
7.1.2 Representative Biopharmaceutical Cmo Product
7.1.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Lonza
7.2 Boehringer Ingelheim GmbH
7.2.1 Company profile
7.2.2 Representative Biopharmaceutical Cmo Product
7.2.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
7.3 Rentschler Biotechnologie GmbH
7.3.1 Company profile
7.3.2 Representative Biopharmaceutical Cmo Product
7.3.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Rentschler Biotechnologie GmbH
7.4 Inno Biologics Sdn Bhd
7.4.1 Company profile
7.4.2 Representative Biopharmaceutical Cmo Product
7.4.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Inno Biologics Sdn Bhd
7.5 JRS Pharma (Celonic GmbH)
7.5.1 Company profile
7.5.2 Representative Biopharmaceutical Cmo Product
7.5.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of JRS Pharma (Celonic GmbH)
7.6 BIOMEVA GmbH
7.6.1 Company profile
7.6.2 Representative Biopharmaceutical Cmo Product
7.6.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of BIOMEVA GmbH
7.7 ProBioGen
7.7.1 Company profile
7.7.2 Representative Biopharmaceutical Cmo Product
7.7.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of ProBioGen
7.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
7.8.1 Company profile
7.8.2 Representative Biopharmaceutical Cmo Product
7.8.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
7.9 TOYOBO CO., LTD
7.9.1 Company profile
7.9.2 Representative Biopharmaceutical Cmo Product
7.9.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of TOYOBO CO., LTD
7.10 Samsung BioLogics
7.10.1 Company profile
7.10.2 Representative Biopharmaceutical Cmo Product
7.10.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Samsung BioLogics
7.11 Patheon
7.11.1 Company profile
7.11.2 Representative Biopharmaceutical Cmo Product
7.11.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Patheon
7.12 CMC Biologics
7.12.1 Company profile
7.12.2 Representative Biopharmaceutical Cmo Product
7.12.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of CMC Biologics
7.13 Binex Co., Ltd.
7.13.1 Company profile
7.13.2 Representative Biopharmaceutical Cmo Product
7.13.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of Binex Co., Ltd.
7.14 AbbVie Inc.
7.14.1 Company profile
7.14.2 Representative Biopharmaceutical Cmo Product
7.14.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of AbbVie Inc.
7.15 WuXi Biologics.
7.15.1 Company profile
7.15.2 Representative Biopharmaceutical Cmo Product
7.15.3 Biopharmaceutical Cmo Sales, Revenue, Price and Gross Margin of WuXi Biologics.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOPHARMACEUTICAL CMO
8.1 Industry Chain of Biopharmaceutical Cmo
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOPHARMACEUTICAL CMO
9.1 Cost Structure Analysis of Biopharmaceutical Cmo
9.2 Raw Materials Cost Analysis of Biopharmaceutical Cmo
9.3 Labor Cost Analysis of Biopharmaceutical Cmo
9.4 Manufacturing Expenses Analysis of Biopharmaceutical Cmo
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOPHARMACEUTICAL CMO
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
